Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 13/20 | 0.74 |
| ▸ | THRA | P10827 | 7/20 | 0.74 |
| ▸ | THRB | P10828 | 7/20 | 0.74 |
| ▸ | PPARG | P37231 | 3/20 | 0.74 |
| ▸ | RXRA | P19793 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | AR | P10275 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14484752 | 0.86 | THRA (0.68) | PCNATHRATHRBPPARGRXRA | |
| Tiratricol SCHEMBL25149 | 0.85 | THRB (1.00) | PCNATHRATHRBPPARGRXRA | |
| Tiratricol SCHEMBL30161572 | 0.85 | THRB (1.00) | PCNATHRATHRBPPARGRXRA | |
| Tiratricol SCHEMBL743426 | 0.85 | THRB (1.00) | PCNATHRATHRBPPARGRXRA | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.85 | PCNA (1.00) | PCNATHRATHRBPPARGRXRA | |
| Tiratricol SCHEMBL8660328 | 0.84 | THRB (0.97) | PCNATHRATHRBPPARGRXRA | |
| SCHEMBL5743343 | 0.84 | PCNA (0.62) | PCNATHRATHRBPPARGRXRA | |
| Tiratricol SCHEMBL2671904 | 0.84 | THRB (0.97) | PCNATHRATHRBPPARGRXRA | |
| SCHEMBL5741869 | 0.84 | PCNA (0.62) | PCNATHRATHRBPPARGRXRA | |
| Tiratricol SCHEMBL10701956 | 0.84 | THRB (0.97) | PCNATHRATHRBPPARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471032-B1 | Substituted glutaurine compounds and substituted glutaurine derivatives | THERMOLIFE INTERNATIONAL, LLC (US) | 2019-11-12 | — | — | US | claimed |
| US-9662304-B1 | Substituted glutaurine compounds and substituted glutaurine derivatives | THERMOLIFE INTERNATIONAL, LLC (US) | 2017-05-30 | — | — | US | claimed |
| WO-2005123099-A2 | METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM | ENZYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ENZYMEDIX | 2005-12-08 | — | — | US | claimed |
| US-12636270-B2 | Levothyroxine liquid formulations | FRESENIUS KABI USA, LLC (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2024262610-A1 | CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME | 国立研究開発法人国立国際医療研究センター | 2024-12-26 | — | — | WO | disclosed |
| US-20240382441-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2024-11-21 | — | — | US | disclosed |
| US-11400068-B2 | Liquid ready-to-use formulation of levothyroxine | SOMERSET THERAPEUTICS LLC (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220096414-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-20210386699-A1 | LIQUID READY-TO-USE FORMULATION OF LEVOTHYROXINE | SOMERSET THERAPEUTICS LLC (US) | 2021-12-16 | — | — | US | disclosed |
| US-11135190-B2 | Levothyroxine liquid formulations | FRESENIUS KABI USA, LLC (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210251931-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | FRESENIUS KABI USA, LLC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-1383729-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005123099-A2 | METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM | ENZYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ENZYMEDIX | 2005-12-08 | — | — | US | disclosed |
| US-20040267015-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-12-30 | — | — | US | disclosed |
| EP-1383729-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002081426-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0536200-B1 | FLUORINE-CONTAINING ACRYLATE AND METHACRYLATE SIDE-CHAIN LIQUID CRYSTAL MONOMERS AND POLYMERS | MINNESOTA MINING & MFG (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5087672-A | Lower birefringence and viscosity, increased hydrophobicity | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267015-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | PCNA 1541/4885THRA 3654/4885THRB 2643/4885 |
| US-20240382441-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | TPO, SSTR5, TSHR | PCNA 4875/4885THRA 11/4885THRB 14/4885 |
| US-12636270-B2 | Levothyroxine liquid formulations | TPO, SSTR5, TRHDE | PCNA 4834/4885THRA 13/4885THRB 12/4885 |
| US-20220096414-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | TPO, SSTR5, TSHR | PCNA 4875/4885THRA 11/4885THRB 14/4885 |
| US-10471032-B1 | Substituted glutaurine compounds and substituted glutaurine derivatives | TSHR, ESRRG, ESRRA | PCNA 3753/4885THRA 11/4885THRB 14/4885 |
| US-20210386699-A1 | LIQUID READY-TO-USE FORMULATION OF LEVOTHYROXINE | TPO, TSHR, TRHR | PCNA 4822/4885THRA 6/4885THRB 12/4885 |
| US-11135190-B2 | Levothyroxine liquid formulations | TPO, SLC5A11, TSHR | PCNA 4872/4885THRA 6/4885THRB 11/4885 |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ADH1A, ADH1C, ADH5 | PCNA 1377/4885THRA 2112/4885THRB 2655/4885 |
| US-20210251931-A1 | LEVOTHYROXINE LIQUID FORMULATIONS | TPO, SSTR5, TSHR | PCNA 4880/4885THRA 11/4885THRB 15/4885 |
| US-11400068-B2 | Liquid ready-to-use formulation of levothyroxine | TPO, TSHR, TRHR | PCNA 4822/4885THRA 6/4885THRB 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.